154 related articles for article (PubMed ID: 21062299)
1. The crossover of bisphosphonates to cancer therapy.
Sun M; Iqbal J; Singh S; Sun L; Zaidi M
Ann N Y Acad Sci; 2010 Nov; 1211():107-12. PubMed ID: 21062299
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor potential of bisphosphonates.
Green JR
Med Klin (Munich); 2000 Oct; 95 Suppl 2():23-8. PubMed ID: 11089384
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates: new therapeutic agents for the treatment of bone tumors.
Heymann D; Ory B; Gouin F; Green JR; Rédini F
Trends Mol Med; 2004 Jul; 10(7):337-43. PubMed ID: 15242682
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of bisphosphonates in cancer therapy.
Lüftner D; Henschke P; Possinger K
Anticancer Res; 2007; 27(4A):1759-68. PubMed ID: 17649770
[TBL] [Abstract][Full Text] [Related]
5. Should bisphosphonates be utilized in the adjuvant setting for breast cancer?
Lipton A
Breast Cancer Res Treat; 2010 Aug; 122(3):627-36. PubMed ID: 20490653
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates in the adjuvant treatment of cancer: experimental evidence and first clinical results. International Bone and Cancer Study Group (IBCG).
Diel IJ; Mundy GR
Br J Cancer; 2000 Apr; 82(8):1381-6. PubMed ID: 10780514
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates in oncology.
Coleman RE; McCloskey EV
Bone; 2011 Jul; 49(1):71-6. PubMed ID: 21320652
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates: expanded roles in the treatment of patients with cancer.
Viale PH; Sanchez Yamamoto D
Clin J Oncol Nurs; 2003; 7(4):393-401. PubMed ID: 12929272
[TBL] [Abstract][Full Text] [Related]
9. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease.
Dunstan CR; Felsenberg D; Seibel MJ
Nat Clin Pract Oncol; 2007 Jan; 4(1):42-55. PubMed ID: 17183355
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates in preclinical bone oncology.
Clézardin P; Benzaïd I; Croucher PI
Bone; 2011 Jul; 49(1):66-70. PubMed ID: 21145441
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy.
Li B; Ling Chau JF; Wang X; Leong WF
J Cell Biochem; 2011 May; 112(5):1229-42. PubMed ID: 21465521
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo antiresorptive effects of bisphosphonates in metastatic bone disease.
Kanakis I; Kousidou OCh; Karamanos NK
In Vivo; 2005; 19(1):311-8. PubMed ID: 15796191
[TBL] [Abstract][Full Text] [Related]
13. The antitumor potential of bisphosphonates.
Clézardin P
Semin Oncol; 2002 Dec; 29(6 Suppl 21):33-42. PubMed ID: 12584693
[TBL] [Abstract][Full Text] [Related]
14. Moving into the future: treatment of bone metastases and beyond.
Hortobagyi GN
Cancer Treat Rev; 2005; 31 Suppl 3():9-18. PubMed ID: 16249057
[TBL] [Abstract][Full Text] [Related]
15. [Current use of bisphosphonates in clinical oncology].
Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V
Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372
[TBL] [Abstract][Full Text] [Related]
16. Potential anticancer properties of bisphosphonates.
Neville-Webbe HL; Gnant M; Coleman RE
Semin Oncol; 2010 Jun; 37 Suppl 1():S53-65. PubMed ID: 20682373
[TBL] [Abstract][Full Text] [Related]
17. Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates.
Green JR
Acta Oncol; 2005; 44(3):282-92. PubMed ID: 16076701
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates: ready for use as adjuvant therapy of breast cancer?
Theriault RL
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):61-6. PubMed ID: 19934757
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates for the prevention of bone metastases.
Coleman RE
Semin Oncol; 2002 Dec; 29(6 Suppl 21):43-9. PubMed ID: 12584694
[TBL] [Abstract][Full Text] [Related]
20. [The application advances of bisphosphonates in bone metastasis].
Liang P
Zhongguo Gu Shang; 2008 Jun; 21(6):480-2. PubMed ID: 19108448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
